LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "cybord" as a keyword



Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

Sign Up to like & get
recommendations! Published in 2020 at "Bone Marrow Transplantation"

DOI: 10.1038/s41409-020-01086-9

Abstract: The combination of bortezomib, cyclophosphamide and dexamethasone (CyBorD or VCD) has been evaluated using different protocols in multiple myeloma (MM). Most of these studies employed twice weekly bortezomib at 1.3 mg/m (days 1, 4, 8,… read more here.

Keywords: response; transplant; disease; cybord ... See more keywords

Chalazion in a patient with multiple myeloma treated with bortezomib

Sign Up to like & get
recommendations! Published in 2022 at "BMJ Case Reports"

DOI: 10.1136/bcr-2022-251077

Abstract: We present a case of a woman in her early 60s with multiple myeloma who, while undergoing treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), noticed a whitish nodular swelling on the eyelid. This occurred after… read more here.

Keywords: myeloma; chalazion patient; patient multiple; cybord ... See more keywords

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Sign Up to like & get
recommendations! Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-130364

Abstract: Introduction: Autologous stem cell transplant (ASCT) is a very effective treatment in AL amyloidosis. However, its role is challenged by novel, powerful, non-transplant therapy, also due to the potentially high treatment-related mortality (TRM) that requires… read more here.

Keywords: response cybord; response; treatment; cybord ... See more keywords

Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Cybord or Daracybord

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-204612

Abstract: Background: A difference between involved and non-involved free light chain (dFLC) exceeding 180 mg/L is part of the 2012 Mayo staging system. However, none of the 758 patients evaluated to develop this staging system received… read more here.

Keywords: light chain; daracybord; cybord daracybord; free light ... See more keywords

Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.

Sign Up to like & get
recommendations! Published in 2020 at "Blood advances"

DOI: 10.1182/bloodadvances.2020002219

Abstract: Autologous stem cell transplant (ASCT) is highly effective in selected patients with light chain (AL) amyloidosis. Bortezomib, preceding or following ASCT, improves responses. Satisfactory responses, including at least a partial response, very good partial response… read more here.

Keywords: response; cybord; stem cell; amyloidosis ... See more keywords

From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis

Sign Up to like & get
recommendations! Published in 2025 at "Blood Advances"

DOI: 10.1182/bloodadvances.2025016586

Abstract: Key points • ASCT for AL amyloidosis decreased significantly (71% average annual reduction) with the introduction of Dara-CyBorD.• ASCT now targets patients with suboptimal response, relapsed/refractory disease, lymphoplasmacytic clone, or higher plasma cell burden. read more here.

Keywords: asct utilization; dara cybord; cybord dara; cybord asct ... See more keywords

Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.

Sign Up to like & get
recommendations! Published in 2021 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2021.39.15_suppl.8035

Abstract: 8035 Background: LYRA is a community practice-based, phase 2, single-arm study (NCT02951819) evaluating DARA + CyBorD as an immunomodulatory drug-sparing regimen in MM. The primary analysis demonstrated the safety and efficacy of DARA + CyBorD… read more here.

Keywords: therapy; maintenance; cybord; study ... See more keywords